600 patients66,869 observations120 daysLIVE

Patient P-01447

Synthetic patientNBL-101 · Day 110 · 55–64 · M · baseline S15Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
60%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S15
  2. Day 45 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 50 GI-04 recommendedGI Support Protocol GI-04
  4. Day 51 Patient acceptedStarted GI-04 in the companion
  5. Day 59 GI symptom burden −27% vs expectedGI Support Protocol GI-04
  6. Day 65 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 45.

Primary contributors, last 14 days
  • Toxicity-15
  • Treatment adherence+4
  • Inflammatory activity+3
  • Nutritional resilience+2

What helped?

  • GI Support Protocol GI-04Day 50
    Result: symptom burden −27%
LIFE OS recommendation
Dietary Support Protocol NP-02
53%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 66% showed improvement
  • median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
60.2/100
stable · +1.7 vs previous 14 d
Toxicity
Blood
38.7/100
improving · -10.7 vs previous 14 d
Sleep quality
Wearable
12.6/100
improving · +2.9 vs previous 14 d
Energy level
Daily log
2.7/10
improving · +0.3 vs previous 14 d
Stress level
Daily log
6/10
improving · -0.5 vs previous 14 d
Steps
Wearable
3,419
improving · +623 vs previous 14 d
Adherence
Companion
49 %
improving · +2.0 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 23 from the failing basin, 67 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 77 similar · onset 3 d · confidence 63%
  • NP-02 Dietary Support Protocol
    63% improved among 64 similar · onset 10 d · confidence 63%
  • SC-12 Supportive Compound
    76% improved among 51 similar · onset 6 d · confidence 63%
Would not help
  • Keep histamine low
    GI +4.9 next day on high-intake days · n 22
  • Keep simple carbs low
    GI +4.7 next day on high-intake days · n 19
  • Keep fat low
    GI +4.4 next day on high-intake days · n 19
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Histamine load
    +4.9detractor · 95%
  • Simple carbohydrates
    +4.7detractor · 95%
  • Dietary fat load
    +4.4detractor · 95%
  • Spicy / capsaicin
    +2.5detractor · 64%
  • Insoluble fibre
    -0.6no signal · 15%
  • Alcohol
    -0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 90
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 60 and rising
    • WearableSleep 5.5 h, below personal baseline
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 38/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 65
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • BloodInflammatory load index 61
    • WearableHRV 38 ms, trending down
  • Autonomic recovery 65
    • WearableResting HR 83 bpm
    • Wearable3,419 steps/day
    • WearableShort sleep window
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Rapid metabolizer
    Expected exposure
  • MTHFR C677T
    Reduced folate turnover
Microbiome
Shannon diversity 2.6 · butyrate capacity 38/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisNormal
  • Bifidobacterium longumLow
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
39 ms
Sleep
5.9 h
Steps
3,509
Resting HR
79 bpm
Daily log: GI score 60, nutritional resilience 38, adherence 49.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0132741%S01GI-04improved56
P-0168841%S01GI-04improved40
P-0181341%S01NP-02no change40
P-0131034%S0157
P-0187729%S01CR-01improved67
P-0182322%S0157
P-0160421%S0171
P-0182121%S0158
P-0184621%S0137
P-0145241%S02GI-04improved46
P-0163540%S02GI-04improved49
P-0145932%S0251